Skip to content
1st Counsel – Lifestyle
Author:
NanoViricides
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
May 4, 2026
Deadly Measles Cases Accentuate the Need for a Treatment – NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
April 21, 2026
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
April 7, 2026
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
April 1, 2026
←
Previous Page
1
2